This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TranS1 Announces CEO Transition

WILMINGTON, N.C., Jan. 4, 2011 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) today announced that its Board of Directors (the "Board") has appointed current President and COO, Ken Reali, as Chief Executive Officer of the Company. Mr. Randall, its current Chief Executive Officer, will continue to serve as a member of the Board in the newly created position of Executive Chairman of the Board. As Executive Chairman, Mr. Randall will continue to play an important role in the management of the Company and will principally be involved with working with Mr. Reali and his management team on building shareholder value in an evolving spine market more focused on cost effective, minimally invasive surgical therapies. In connection with his appointment as Chief Executive Officer, Mr. Reali is also being elected as a member of the Board.

"Rick has been instrumental in the development of TranS1 since joining the Company in 2002 and we are pleased that he will continue to serve as Executive Chairman of the Board," said Paul LaViolette, Lead Director of TranS1. "Ken has made a significant impact on TranS1 since he joined last year and we are enthusiastic about his leading the Company forward."

Mr. Reali was initially hired by the Company as President and Chief Operating Officer in January 2010. He has over 20 years of general management, sales and marketing experience with leading medical device and orthopedic companies. Mr. Reali joined the Company from Smith & Nephew where he spent five years in various senior marketing, sales and product development positions, including most recently as Senior Vice President and General Manager of the Biologics and Clinical Therapies Business. Prior to joining Smith & Nephew, Mr. Reali held senior marketing, sales and product development positions at Stryker for seven years. Prior to joining Stryker, Mr. Reali worked as a territory and product manager at Biomet for eight years.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.32 -3.92%
YHOO $36.02 -1.40%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs